Osimertinib-related skin and mucosal adverse events

Juan José García Mosquera, Eudald Felip, Adrià Plana, Aram Boada, Laura Angelats, Maria Josefa Fuente, Enric Carcereny, Iris Teruel, Teresa Moran

Research output: Contribution to journalArticleResearchpeer-review


© 2017 Elsevier Ltd Toxicities related to osimertinib have been reported with lower incidence and grade as compared to other tyrosin kinase inhibitors. The present report includes previously unreported adverse events related to osimertinib. These toxicities are a reminder of potential novel toxicities related to new drugs and highlight the need for a multidisciplinary approach to recognize and treat such adverse events.
Original languageEnglish
Pages (from-to)53-55
JournalCancer Treatment and Research Communications
Publication statusPublished - 1 Jan 2017


  • Epidermal growth factor receptor (EGFR)
  • Nasal vestibulitis
  • Osimertinib
  • Skin adverse events
  • Toxicoderma

Fingerprint Dive into the research topics of 'Osimertinib-related skin and mucosal adverse events'. Together they form a unique fingerprint.

Cite this